Adrenocortical carcinoma (ACC), a rare cancer originating in the adrenal cortex, comprises a minute fraction of overall cancer cases. Its subtle symptoms pose diagnostic challenges, necessitating intensified research efforts. In the realm of cancer research, ACC is a focal point for unraveling its intricate genetic and molecular underpinnings. Through genomic sequencing, pivotal mutations linked to ACC are identified, unveiling potential therapeutic targets. Moreover, emphasis is laid on refining diagnostic modalities and biomarkers to facilitate early detection and prognosis prediction. Collaborative ventures among researchers and clinicians aim at optimizing treatment paradigms, encompassing surgery, chemotherapy, and radiation therapy, to augment patient outcomes. Despite its rarity, persistent investigative pursuits aim to decode the complexities surrounding ACC, promising advancements in diagnosis, treatment, and patient care.
Title :
Patricia Tai, Saskatchewan Cancer Agency, Canada
Title :
Atif A Ahmed, Seattle Children’s Hospital, United States
Title :
Marika Crohns, Sanofi, Germany
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title : The future of pharmacogenetic polymorphism, pharmacogenomics and pharmamicrobiome in cancer treatment
Bene Ekine-Afolabi, University of East London, United Kingdom
Title : Biosensor-based detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada